Figure 2.

Proportion of true-negative and false-positive results for PfHPR2 and PfLDH according to the treatment during follow-up. (SP: sulphadoxine-pyrimethamine; ASAQ: artesunate-amodiaquine, AL: artemether-lumefantrine). Statistical analysis of antigen detection specificities for ACT compared to SP and for PfLDH compared to PfHPR2 are shown on the right: ***: p0.001; **: p < 0.01: *: p < 0.05, ns: not significant.